Skip to main content
TipRanks
Go Ultimate75% OFF

Entrada Therapeutics Inc (TRDA) Drug Pipeline

164 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Entr-601-45Duchenne Muscular Dystrophy (Dmd)phase1AndPhase2Not Yet RecruitingA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45May 01, 2025―
Entr-601-44Duchenne Muscular Dystrophy (Dmd)phase1AndPhase2RecruitingA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44May 01, 2025―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Entrada Therapeutics Inc (TRDA) have in its pipeline
Entrada Therapeutics Inc TRDA is currently developing the following drugs: Entr-601-45, Entr-601-44. These drug candidates are in various stages of clinical development as the company works toward FDA approval.